GeneSet Information

Tier I GS268626 • GWAS Catalog Data for response to radiation, prostate carcinoma in 1,346 European ancestry individuals

DESCRIPTION:

List of positional candidate genes after correcting for multiple testing and controlling the false discovery rate from genome wide association studies (GWAS) retrieved from the NHGRI-EBI Catalog of published genome-wide association studies (http://www.ebi.ac.uk/gwas/). The disease/trait examined in this study, as reported by the authors, was Response to radiotherapy in prostate cancer (overall toxicity). The EFO term response to radiation, prostate carcinoma was annotated to this set after curation by NHGRI-EBI. Intergenic SNPS were mapped to both the upstream and downstream gene. P-value uploaded. This gene set was generated using gwas2gs v. 0.1.8 and the GWAS Catalog v. 1.0.1.

LABEL:

GWAS: response to radiation, prostate carcinoma

SCORE TYPE:

P-Value

DATE ADDED:

2017-05-02

DATE UPDATED:

2024-04-25

SPECIES:

AUTHORS:

SL Kerns, L Dorling, L Fachal, S Bentzen, PD Pharoah, DR Barnes, A Gómez-Caamaño, AM Carballo, DP Dearnaley, P Peleteiro, SL Gulliford, E Hall, K Michailidou, Á Carracedo, M Sia, R Stock, NN Stone, MR Sydes, JP Tyrer, S Ahmed, M Parliament, H Ostrer, BS Rosenstein, A Vega, NG Burnet, AM Dunning, GC Barnett, CM West

TITLE:

Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer.

JOURNAL:

EBioMedicine Aug 2016, Vol 10, pp. 150-63

ABSTRACT:

Nearly 50% of cancer patients undergo radiotherapy. Late radiotherapy toxicity affects quality-of-life in long-term cancer survivors and risk of side-effects in a minority limits doses prescribed to the majority of patients. Development of a test predicting risk of toxicity could benefit many cancer patients. We aimed to meta-analyze individual level data from four genome-wide association studies from prostate cancer radiotherapy cohorts including 1564 men to identify genetic markers of toxicity. Prospectively assessed two-year toxicity endpoints (urinary frequency, decreased urine stream, rectal bleeding, overall toxicity) and single nucleotide polymorphism (SNP) associations were tested using multivariable regression, adjusting for clinical and patient-related risk factors. A fixed-effects meta-analysis identified two SNPs: rs17599026 on 5q31.2 with urinary frequency (odds ratio [OR] 3.12, 95% confidence interval [CI] 2.08-4.69, p-value 4.16×10(-8)) and rs7720298 on 5p15.2 with decreased urine stream (OR 2.71, 95% CI 1.90-3.86, p-value=3.21×10(-8)). These SNPs lie within genes that are expressed in tissues adversely affected by pelvic radiotherapy including bladder, kidney, rectum and small intestine. The results show that heterogeneous radiotherapy cohorts can be combined to identify new moderate-penetrance genetic variants associated with radiotherapy toxicity. The work provides a basis for larger collaborative efforts to identify enough variants for a future test involving polygenic risk profiling. PUBMED: 27515689
Find other GeneSets from this publication

Annotation Information

No sequence read archive data associated with this GeneSet.


prostate carcinoma (EFO:0001663)

Gene List • 40 Genes

Uploaded As Gene Symbol Homology Score Priority LinkOuts Emphasis